iPS-T cell therapy

iPS-T cell therapy is a form of cell therapy in which **T cells are generated from human induced pluripotent stem cells (iPSCs)**, often for adoptive immunotherapy, including cancer and autoimmune indications. iPSCs can be differenti­ated into T cells with defined antigen specificity through genetic engineering, such as introducing specific T cell receptors (TCRs) or chimeric antigen receptors (CARs). This approach enables the production of *off-the-shelf* T cell products with unlimited scalability and potential for standardization, hypo-immunogenicity, and rigorous safety testing. iPSC-derived T cells can have enhanced proliferative capacity and memory-like features, extending their anti-tumor efficacy relative to conventional effector T cells. The therapy addresses limitations of autologous T cell manufacturing, such as donor variability and supply constraints, by providing a consistent, renewable cell source suitable for large-scale GMP manufacturing[2][4][7][9][14]. Main mechanisms involve immune targeting of disease—typically cancer—using engineered antigen recognition. This therapy is in experimental and early clinical phases and is being developed for oncological and autoimmune diseases.

Other names

iPSC-derived T cell therapyiPSC-T cell therapyiT cell therapy